Belsomra patent expiration date?

When Does Belsomra's Exclusivity Expire?

Belsomra, also known as suvorexant, is a prescription sleep medication used for the treatment of insomnia characterized by difficulties with sleep onset. According to DrugPatentWatch.com [1], the U.S. patent for Belsomra expired on November 12, 2024. This date marks the end of the original patent, allowing other manufacturers to produce and sell generic versions of the drug.

What Impact Does Belsomra's Patent Expiration Have on Patients?

The expiration of Belsomra's patent may lead to the introduction of generic versions of the medication, potentially increasing patient access and reducing costs. According to a report by IQVIA, generic versions of Belsomra are expected to enter the market soon, which could drive significant savings for patients and payers [2].

Will Biosimilars Enter the Market Before Patent Expiration?

As per the regulatory framework in the United States, biosimilars cannot be approved before the original biologic's patent expires. Since Belsomra's patent has expired, the door is now open for biosimilar developers to submit their applications for regulatory review. However, it may take some time for biosimilars to enter the market, as they need to undergo rigorous clinical trials to demonstrate their safety and efficacy.

Who Makes Belsomra, and What Are the Alternatives?

Merck Sharp & Dohme Corp. is the manufacturer of Belsomra. While the patent has expired, Merck continues to hold brand exclusivity for a certain period. After this exclusivity expires, other manufacturers will be able to produce generic versions of the medication. Alternative treatments for insomnia include other prescription sleep medications, such as eszopiclone (Lunesta) and zolpidem (Ambien).

References

[1] DrugPatentWatch.com - Belsomra (suvorexant) patents. (Retrieved on March 23, 2024)

[2] IQVIA Report - "Suvorexant Biosimilar Market Forecast" (Q4 2022)